TABLE 1.
Baseline characteristics of intention‐to‐treat analysis population.
| Culture‐based tailored therapy | Empirical concomitant therapy | p value | |
|---|---|---|---|
| (n = 234) | (n = 78) | ||
| Age | 0.739 | ||
| Mean ± SD | 60.1 ± 10.2 | 60.5 ± 10.8 | |
| Range | 28–82 | 31–79 | |
| Gender | 0.225 | ||
| Male (%) | 141 (60.3) | 53 (67.9) | |
| Female (%) | 93 (39.7) | 25 (32.1) | |
| BMI | |||
| Mean ± SD | 24.3 ± 3.1 | 24.2 ± 2.6 | 0.767 |
| Smoking | 0.725 | ||
| Never‐smoker (%) | 149 (63.7) | 46 (59.0) | |
| Ex‐smoker (%) | 56 (23.9) | 22 (28.2) | |
| Current‐smoker (%) | 29 (12.4) | 10 (12.8) | |
| Alcohol drinking | 0.800 | ||
| Never‐drinker (%) | 97 (41.5) | 29 (37.2) | |
| Ex‐drinker (%) | 62 (26.5) | 22 (28.2) | |
| Current‐drinker (%) | 75 (32.1) | 27 (34.6) | |
| Indication for eradication | 0.365 | ||
| Atrophic gastritis (%) | 79 (33.8) | 23 (29.5) | |
| Gastric ulcer (%) | 8 (3.4) | 4 (5.1) | |
| Duodenal ulcer (%) | 8 (3.4) | 6 (7.7) | |
| Gastric neoplasm (%) | 139 (59.4) | 45 (57.7) | |
| Clarithromycin | 0.556 | ||
| Susceptible (%) | 169 (72.2) | 59 (75.6) | |
| Resistant (%) | 65 (27.8) | 19 (24.4) | |
| Metronidazole | 0.352 | ||
| Susceptible (%) | 183 (78.2) | 57 (73.1) | |
| Resistant (%) | 51 (21.8) | 21 (26.9) | |
| Dual‐susceptible (%) | 137 (58.5) | 44 (56.4) | 0.741 |
| Dual‐resistant (%) | 19 (8.1) | 6 (7.7) | 0.904 |
Abbreviation: BMI, body mass index.